

THERASPHERE™
Y-90 Glass Microspheres

SIMPLICIT^{90Y}™
Personalised Dosimetry Software

EMBRACE ⁹⁰Y SIRT PERSONALISED DOSIMETRY



PERSONALISING THERASPHERE TREATMENT SIMPLIFYING SIRT WORKFLOW

A MULTI-DISCIPLINARY APPROACH




Optimised SIRT requires a multidisciplinary approach, and strong collaboration between **clinicians, interventional radiology and nuclear medicine.**

A RAPID WORKFLOW WITH SIMPLICIT^{90Y}



A comprehensive **dosimetry software** allowing Interventional Radiologists, Nuclear Medicine Physicians and Medical Physicists to implement personalised ⁹⁰Y SIRT with TheraSphere in clinical routine.

CLINICAL & DOSIMETRY GUIDELINES



Implementation of **TheraSphere personalised dosimetry** is supported by specific guidelines and **recommendations from Salem et al,¹** an international multidisciplinary working group of experts in liver cancer.

“**Predictive dosimetry based on ^{99m}Tc-MAA SPECT/CT must be adopted in clinical routine for HCC patients treated with TheraSphere.**”

Prof. Etienne Garin
Nuclear Medicine Physician
Rennes Cancer Center, France


“**This is Level 1 evidence that shows better outcomes in gold-standard survival, and in trying to convert patients to resection. A win-win-win on all fronts.**”

Prof. Riad Salem
Interventional Radiologist
Northwestern University, Chicago/IL USA

DOSISPHERE-01

Level 1 Evidence for Improved Patient Outcomes

A prospective, randomised, multi-centre, phase II trial that looked at HCC patients treated with TheraSphere using either personalised dosimetry or standard dosimetry.



The DOSISPHERE-01 study demonstrated significant benefits in terms of tumour response and overall survival for patients who received personalised dosimetry with TheraSphere, opening a pathway to cure.



Embrace Personalised Dosimetry with TheraSphere and Simplicit^{90Y}

Compelling Evidence for ⁹⁰Y SIRT

Compelling Evidence for Personalised Dosimetry



Find out more about
Personalised Dosimetry

[Visit our website](#)

References:

1. Salem R, Padia SA, Lam M, *et al.* Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group. *Eur J Nucl Med Mol Imaging.* 2019; 46(8):1695-1704. doi:10.1007/s00259-019-04340-5.
2. COUNCIL DIRECTIVE 2013/59/EURATOM, OFFICIAL JOURNAL OF THE EUROPEAN UNION. 2014.
3. Garin E, Tselikas L, Guiu B, Chalaye J *et al.* *Lancet Gastroenterol Hepatol.* 2020; Nov 6:S2468-1253(20)30290-9. doi: 10.1016/S2468-1253(20)30290-9. Epub ahead of print. PMID: 33166497.

Simplicit^{90Y} was developed in conjunction with Boston Scientific and Mirada Medical and is manufactured by:

Mirada Medical Ltd
New Barclay House
234 Botley Road
Oxford OX2 0HP
United Kingdom

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.

**Boston
Scientific**
Advancing science for life™

2020 Copyright
© Boston Scientific Corporation
or its affiliates. All rights reserved.
PI-930006-AA